Commentary: A new biotechnology and pharmaceutical industry commitment to patients and the public

A group of 215 leaders in the biotechnology and pharmaceutical industries, academia, and life science investors issued a "New Commitment to Patients" on Wednesday, emphasizing the need to always put the interests of patients first. The coalition focused on ensuring access to medicines with pricing that reflects innovation and value to patients.

A group of 215 leaders in the biotechnology and pharmaceutical industries, academia, and life science investors issued a "New Commitment to Patients" on Wednesday, emphasizing the need to always put the interests of patients first. The coalition focused on ensuring access to medicines with pricing that reflects innovation and value to patients. "To achieve the goal of patient access, we will collaborate with policymakers, PBMs, payers, and providers to find ways to limit or eliminate copays and deductibles for all patients," the group states. "We will support generic and biosimilar approvals of safe and effective medicines after legitimate patent and regulatory protections expire. We will seek to collaborate with all key parties in the health care system, including all biopharmaceutical companies, hospitals, pharmacies, distributors, and policymakers, to ensure that all patients get access to the medicines they need." The coalition also vows to invest only in novel therapies that address unmet patient needs, and commits to "patient advocacy in how we build and operate our companies, and to connecting directly with patients and their families."